RiverFront Investment Group’s Vertex Pharmaceuticals VRTX Stock Holding History

RiverFront Investment Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$490K	Buy	987 +58	+6%	+$25.7K	0.01%	301
2026 Q1	$415K	Buy	929 +30	+3%	+$14K	0.01%	282
2025 Q4	$408K	Sell	899 -9	-1%	-$3.88K	0.01%	255
2025 Q3	$356K	Sell	908 -79	-8%	-$33K	0.01%	244
2025 Q2	$439K	Buy	987 +375	+61%	+$173K	0.01%	216
2025 Q1	$297K	Buy	+612	New	+$285K	0.01%	239
2021 Q3	–	Sell	-1,125	Closed	-$227K	–	136
2021 Q2	$227K	Buy	1,125 +44	+4%	+$9.2K	﹤0.01%	135
2021 Q1	$232K	Buy	1,081 +158	+17%	+$34.7K	﹤0.01%	107
2020 Q4	$218K	Buy	+923	New	+$212K	﹤0.01%	90

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

RiverFront Investment Group's VRTX Position: Q2 2026 in Review

RiverFront Investment Group increased its Vertex Pharmaceuticals (VRTX) stake by 6.2% in Q2 2026, buying an estimated $25.7K and bringing the position to 987 shares worth $490K. The position accounts for 0.01% of the portfolio, ranked #301.

RiverFront Investment Group first reported a position in VRTX in Q4 2020 and has held it in 9 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

RiverFront Investment Group held 987 shares of Vertex Pharmaceuticals worth $490K as of Q2 2026.
RiverFront Investment Group bought 58 Vertex Pharmaceuticals shares in Q2 2026, an estimated $25.7K.
Vertex Pharmaceuticals made up 0.01% of RiverFront Investment Group's portfolio in Q2 2026, its #301 holding.
RiverFront Investment Group first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 9 quarters since.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on RiverFront Investment Group's 13F filing for Q2 2026, filed 29 Jul 2026.